Supplemental material
Modern Rheumatology
Volume 29, 2019 - Issue 5
Original Article
Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study
Atsushi OgataDepartment of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Osaka, Japan; ;Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan; Correspondence[email protected]
http://orcid.org/0000-0003-3944-3442View further author information
http://orcid.org/0000-0003-3944-3442View further author information, , , , , , & the SHINOBI Study Group show all